Stay updated with breaking news from Pikevax. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The European Commission has authorised the Spikevax XBB.1.5-adapted COVID-19 vaccine, developed by Moderna. It is the third adaptation of this vaccine to respond to new COVID-19 variants.
Canadian health officials on Tuesday authorized Moderna's COVID-19 vaccine targeting the Omicron subvariant, urging all Canadians over the age of six months to get fresh inoculations as the nation sees an uptick in infections. Health Canada said in a statement that it has determined that the Moderna SPIKEVAX COVID-19 vaccine targeting the Omicron XBB.1.5 vaccine meets the department’s stringent safety, efficacy and quality requirements. "We are absolutely encouraging people to get protected both with COVID-19 vaccine and the flu shot," Canada's Chief Public Health Officer Theresa Tam said during a news conference after the announcement, adding that Canadians can expect to start receiving the new shots in the beginning of October.
Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and olderTwo-dose series
Data indicate durable immune response from bivalent booster after three months of follow-upmRNA-1273.214 also demonstrated potent response to Omicron BA.2.75CAMBRIDGE, MA / ACCESSWIRE / October 19, 2022
Izah Azahari The Brunei Darussalam Medicines Control Authority (BDMCA) has approved the emergency use authorisation (EUA) for the use of the Moderna Spikevax Bivalent Original/Omicron for adults in the Sultanate. This was announced by Minister of Health Dato Seri Setia Dr Haji Mohd Isham bin Haji Jaafar at a press conference at the Al-’Afiah Hall […]
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced a 30 µg booster dose of their Omicron BA.1- Bivalent COVID-19 Vaccine, COMIRNATY Original, has been recommended for
The UK, EU, and the US are repurposing the current vaccines for the fall and winter booster campaign incorporating Omicron-specific targets. However, the nature of the virus and meager-quality data suggests these will have limited benefit. The shift in commercializing these therapeutics and vaccines will see the vaccine-only strategy wither.